You are here: Industry Insights > Jakavi

News List

Novartis' Jakavi bests current therapy for GvHD pharmatimes
April 26, 2020
Results of the Phase III REACH2 study show that Novartis' Jakavi (ruxolitinib) improves outcomes across a range of efficacy measures in patients with steroid-refractory acute graft-versus-host disease (GvHD) compared to best available therapy (BAT).
Novartis announces plan to initiate clinical study of Jakavi® in severe COVID-19 patients and establish international compassionate use program worldpharmanews
April 08, 2020
Novartis announced plans to initiate a Phase III clinical trial in collaboration with Incyte to evaluate the use of Jakavi® (ruxolitinib) for treatment of a type of severe immune overreaction ...
Novartis and Incyte to trial Jakavi for Covid-19 pharmaceutical-technology
April 06, 2020
Novartis, in alliance with Incyte, has announced plans to evaluate Jakavi (ruxolitinib) in a Phase III clinical trial to treat cytokine storm in patients with severe Covid-19 pneumonia.
Novartis, Incyte to test Jakavi for coronavirus-linked cytokine storm pharmatimes
April 03, 2020
Novartis and Incyte are planning to launch a clinical study to test the potential of Jakavi (ruxolitinib) in patients with COVID-19 associated cytokine storm.